Revenue
5Y CAGR −0.3%5Y CAGR −0.3%$29.8B FY26
FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
No quarters filed for this figure.
TAK
$21.43+1.47%
as of close, Nov 13, 2026
☾ AH $21.43 +1.47%
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)Stock · HealthcareJapanese Stock Market · 1.1% of EWJMSCI EAFE · 0.2% of EFAMSCI World · 0.06% of URTHMSCI ACWI · 0.05% of ACWI
Head-to-head:Compare with HLN or any ticker →
TAK financial statements
The full income statement, balance sheet, and cash-flow statement for Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Financial overview#
Gross profit
5Y CAGR −1.4%5Y CAGR −1.4%$19.4B FY26
FY18FY19FY20FY21FY22FY23FY24FY25FY26
No quarters filed for this figure.
Operating income
5Y CAGR −61.4%5Y CAGR −61.4%$41.1M FY26
FY18FY19FY20FY21FY22FY23FY24FY25FY26
No quarters filed for this figure.
Net income
5Y n/m5Y n/m−$1B FY26
FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
No quarters filed for this figure.
EPS (diluted)
5Y n/m5Y n/m−$0.32 FY26
FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
No quarters filed for this figure.
Operating cash flow
5Y CAGR −6.3%5Y CAGR −6.3%$6.9B FY26
FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
No quarters filed for this figure.
Capital expenditure
5Y CAGR +2.4%5Y CAGR +2.4%— FY26
FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
No quarters filed for this figure.
Free cash flow
5Y CAGR +2.4%5Y CAGR +2.4%— FY26
FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
No quarters filed for this figure.
Shares (diluted)
5Y +0.1%5Y +0.1%3.2B FY26
FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
No quarters filed for this figure.
Dividend per share
5Y CAGR −5.0%5Y CAGR −5.0%YoY +12.3%$0.65 FY26— Q4 '26
FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q3 '20Q4 '20Q1 '21Q3 '21Q4 '21Q1 '22Q3 '22Q4 '22Q1 '23Q3 '23Q4 '23Q1 '24Q3 '24Q4 '24Q1 '25Q3 '25Q4 '25Q1 '26Q3 '26Q4 '26
Shares outstanding (point-in-time)
2018-03 1.59B2019-03 3.13B2020-03 3.12B2021-03 3.15B2022-03 3.16B2023-03 3.16B2024-03 3.16B2025-03 3.18B2026-03 3.15B+98.2% over 8 periods
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
PeriodRangeOrderChangeFiguresAs-reported fiscal years.
| Line item | Trend | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|---|
| Income Statement | as ofMar 31 ’26 | as ofMar 31 ’25 | as ofMar 31 ’24 | as ofMar 31 ’23 | as ofMar 31 ’22 | |
| Revenue | 29.8B-0.9% | 30.0B+2.0% | 29.5B-0.9% | 29.7B-6.4% | 31.8B+5.3% | |
| 19.4B-1.5% | 19.7B+0.4% | 19.6B-4.6% | 20.6B-6.2% | 21.9B+5.4% | ||
| Cost of revenue | 10.4B+0.2% | 10.4B+5.1% | 9.86B+7.3% | 9.19B-6.7% | 9.85B+5.0% | |
| Research & development | 4.47B-6.7% | 4.79B-5.1% | 5.04B+7.8% | 4.68B-0.1% | 4.68B+8.9% | |
| Operating income | 41.1M-98.2% | 2.25B+51.9% | 1.48B-59.2% | 3.62B-11.7% | 4.10B-14.6% | |
| Interest expense | 2.36B+71.6% | 1.38B-9.3% | 1.52B+21.2% | 1.25B-15.5% | 1.48B-36.8% | |
| Pre-tax income | -941M-182.0% | 1.15B+214.7% | 365M-86.8% | 2.77B+2.9% | 2.69B-22.0% | |
| Income tax | 64.6M-85.3% | 439M+169.5% | -632M-247.3% | 429M-33.5% | 644M+787.6% | |
| -1.01B-241.8% | 709M-28.8% | 996M-57.4% | 2.34B+14.3% | 2.05B-42.3% | ||
| Net income to common | -1.01B-242.3% | 708M-28.9% | 996M-57.5% | 2.34B+14.3% | 2.05B-42.3% | |
| -$0.32-245.1% | $0.22-30.0% | $0.31-57.8% | $0.75+14.9% | $0.65-42.4% | ||
| EPS (basic) | -$0.32-242.7% | $0.22-29.6% | $0.32-57.8% | $0.75+15.2% | $0.65-42.3% | |
| Weighted-avg shares (basic) | 3.15B-0.2% | 3.16B+0.9% | 3.13B+0.8% | 3.10B-0.7% | 3.13B+0.1% | |
| Weighted-avg shares (diluted) | 3.15B-1.9% | 3.21B+1.6% | 3.16B+0.7% | 3.14B-0.5% | 3.15B+0.2% | |
| Dividends per share | $0.65+5.0% | $0.62-0.6% | $0.63-3.8% | $0.65-18.3% | $0.80-5.9% | |
| Balance Sheet | as ofMar 31 ’26 | as ofMar 31 ’25 | as ofMar 31 ’24 | as ofMar 31 ’23 | as ofMar 31 ’22 | |
| 19.5B+15.8% | 16.8B-0.5% | 16.9B-6.4% | 18.1B-15.3% | 21.3B-13.0% | ||
| Cash & equivalents | 3.75B+46.0% | 2.57B-15.1% | 3.02B-24.7% | 4.02B-42.5% | 6.98B-20.0% | |
| Accounts receivable | 5.32B+12.4% | 4.73B+7.1% | 4.42B-9.7% | 4.89B-14.6% | 5.73B-19.1% | |
| Inventory | 8.80B+8.4% | 8.12B+1.6% | 7.99B+7.6% | 7.43B+6.0% | 7.01B+3.0% | |
| 97.7B+2.9% | 95.0B-4.8% | 99.8B-5.1% | 105B-2.9% | 108B-7.1% | ||
| Property, plant & equipment | — | — | — | 12.7B-2.1% | 13.0B-0.9% | |
| Goodwill | 36.6B+3.1% | 35.5B-0.7% | 35.7B-1.0% | 36.1B-0.4% | 36.2B-0.6% | |
| Total non-current assets | 78.3B+0.1% | 78.2B-5.7% | 82.9B-4.8% | 87.1B+0.1% | 87.0B-5.6% | |
| Total current liabilities | 17.8B+6.8% | 16.7B+9.4% | 15.3B-18.3% | 18.7B+6.0% | 17.6B+10.1% | |
| 50.9B+4.4% | 48.8B-5.8% | 51.8B-9.6% | 57.3B-7.0% | 61.6B-11.8% | ||
| Long-term debt | 27.5B+4.1% | 26.4B-10.6% | 29.6B-2.9% | 30.5B-10.5% | 34.0B-18.3% | |
| 46.8B+1.2% | 46.2B-3.7% | 48.0B+0.4% | 47.9B+2.5% | 46.7B-0.0% | ||
| Total equity incl. non-controlling | 46.8B+1.2% | 46.3B-3.7% | 48.1B+0.4% | 47.9B+2.5% | 46.7B-0.1% | |
| Common shares outstanding | — | 3.18B+0.5% | 3.16B+0.0% | 3.16B+0.0% | 3.16B+0.4% | |
| Cash Flow | as ofMar 31 ’26 | as ofMar 31 ’25 | as ofMar 31 ’24 | as ofMar 31 ’23 | as ofMar 31 ’22 | |
| 6.88B-0.7% | 6.93B+40.1% | 4.95B-31.4% | 7.22B-27.8% | 10.00B+4.8% | ||
| Depreciation & amortization | 4.77B-4.5% | 4.99B-0.7% | 5.03B+2.5% | 4.91B-5.5% | 5.19B-1.7% | |
| Capital expenditure | — | 1.32B+8.6% | 1.21B+16.7% | 1.04B-5.3% | 1.10B+4.6% | |
| Free cash flow | — | 5.62B+50.2% | 3.74B-39.5% | 6.18B-30.6% | 8.90B+4.9% | |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long-term debt issued | 3.87B-42.3% | 6.72B+872.2% | 691M+24.8% | 554M-75.0% | 2.22B-80.1% | |
| Long-term debt repaid | 1.32B-84.7% | 8.66B+290.7% | 2.22B-15.8% | 2.63B-63.5% | 7.21B-53.7% | |
| Common stock issued | 7.84M-96.7% | 237M+6739.1% | 3.47M+186.4% | 1.21M-99.4% | 197M+47410.8% | |
| Common stock repurchased | 341M+0.2% | 340M+1981.8% | 16.4M-91.8% | 200M-71.7% | 707M+3401.5% | |
| Dividends paid | 2.06B+3.9% | 1.98B-0.0% | 1.98B-3.8% | 2.06B-18.3% | 2.52B-5.5% | |
| Valuation Ratios | as ofMar 31 ’26 | as ofMar 31 ’25 | as ofMar 31 ’24 | as ofMar 31 ’23 | as ofMar 31 ’22 | |
| Market cap | 58.3B+23.3% | 47.3B | — | 52.2B+15.1% | 45.3B-21.3% | |
| P/E | — | 66.7× | — | 22.3×+0.7% | 22.1×+36.3% | |
| P/S | 2.0×+24.4% | 1.6× | — | 1.8×+22.9% | 1.4×-25.3% | |
| P/B | 1.2×+21.8% | 1.0× | — | 1.1×+12.3% | 1.0×-21.3% | |
| P/FCF | — | 8.4× | — | 8.4×+65.8% | 5.1×-24.9% | |
| Earnings yield | — | 1.5% | — | 4.5%-0.7% | 4.5%-26.7% | |
| FCF yield | — | 11.9% | — | 11.8%-39.7% | 19.6%+33.2% | |
| Dividend yield | 3.5%-15.7% | 4.2% | — | 4.0%-29.0% | 5.6%+20.0% | |
| Source filing | 20-F | 20-F | 20-F | 20-F | 20-F |
About this data
Source: TAK’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all TAK filings on SEC EDGAR → Not investment advice.
Head-to-head:Compare with HLN or any ticker →